KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
Volume: 383, Issue: 13, Pages: 1207 - 1217
Published: Sep 24, 2020
Abstract
No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. Patients received sotorasib orally once...
Paper Details
Title
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
Published Date
Sep 24, 2020
Volume
383
Issue
13
Pages
1207 - 1217
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History